Figure 1
Figure 2
Findings on patient characterization at initial diagnosis and after systemic therapy
| N. of patients (%) | N. of patients (%) | N. of patients (%) | |
|---|---|---|---|
| Tumour stage | pT1 | pT2 | pT3/4 |
| Total 18 patients | 7 (38.9) | 7 (38.9) | 4 (22.2) |
| Post-PST | ypT1 | ypT2 | ypT3/4 |
| Total of 15 patients | 2 (13.3) | 8 (53.3) | 5 (33.3) |
| Nodal stage | pNo | pN1 | pN2/3 |
| Total of 22 patients | 8 (36.3) | 6 (27.2) | 8 (36.3) |
| Post-PST | Nodal stage not determined | ypN2/3 | |
| Total of 11 patients | 4 (36.3) | 7 (63.6) |
Systemic therapy at the time of electrochemotherapy
| Monochemotherapy | N. of patients |
|---|---|
| Eribulin | 8 |
| Taxane | 4 |
| Vinorelbine | 3 |
| Capecitabine | 3 |
| Mitomycin | 1 |
| Pegylated liposomal doxorubicin | 1 |
| Combo-chemotherapy | |
| Carboplatin & gemcitabine | 3 |
| Vinorelbine & capecitabine | 1 |
| Antibody therapy | |
| Trastuzumab | 6 |
| Bevacizumab | 4 |
| Endocrine monotherapy | |
| AI with everolimus & fulvestrant | 5 |
Findings of locoregional recidivism prior to electrochemotherapy
| Areas of treated thorax wall | N. of patients (%) |
|---|---|
| On one side | 23 (69.7) |
| On two sides | 7 (21.2) |
| + axilla | 5 |
| + upper arm | 3 |
| + dorsal | 5 |
| + supra/infraclavicular | 1 |
Data on 33 patients at time of the first electrochemotherapy
| Metastasis localization | N. of patients (%) |
|---|---|
| Loco-regional - exclusively | 12 (36.3) |
| Loco-regional + distal | 21 (63.6) |
| Distant metastasis | |
| 1 organ affected | 15 (45.4) |
| 2 organs affected | 3 (9) |
| > 2 organs affected | 3 (9) |
| Distant metastasis and organs affected | |
| Metastases → pulmonary/pleural | 11 (33) |
| Metastases → bone | 10 (30.3) |
| Metastases → cerebral | 3 (9) |
| Metastases → hepatic | 3 (9) |